Dr. Viswanathan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Wac 615
Boston, MA 02114Phone+1 617-726-2674Fax+1 617-724-0393
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2013 - 2017
Massachusetts General HospitalResidency, Internal Medicine, 2011 - 2014
Harvard Medical SchoolClass of 2011
Yale UniversityB. S., M.S., 2000 - 2004
Certifications & Licensure
MA State Medical License 2013 - 2026
NH State Medical License 2024 - 2024
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 2 citationsOncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinoma.Jiao Li, Kaimeng Huang, Meha Thakur, Fiona McBride, Ananthan Sadagopan
Nature Metabolism. 2025-03-01 - CDK4/6 Inhibition With Abemaciclib in Patients With Previously Treated Advanced Renal Cell Carcinoma.Bradley A McGregor, Wanling Xie, Stephanie A Berg, Wenxin Xu, Srinivas R Viswanathan
Clinical Genitourinary Cancer. 2025-02-18 - A framework for target discovery in rare cancers.Bingchen Li, Ananthan Sadagopan, Jiao Li, Yuqianxun Wu, Yantong Cui
Biorxiv. 2024-11-20
Journal Articles
- Genome-Scale Analysis Identifies Paralog Lethality as a Vulnerability of Chromosome 1p Loss in CancerWilliam C Hahn, Srinivas R Viswanathan, Nature
Press Mentions
The Male X Chromosome Is Silenced in Some Cancer TypesDecember 30th, 2022- Scientists Discover X Chromosomes Being 'Silenced' in Male Cancer CellsNovember 15th, 2022
Grant Support
- Probing the role of somatic X-chromosome alterations in shaping cancer sex differencesDANA-FARBER CANCER INST2023–2028
- Regulation of androgen receptor signaling in prostate cancer by protein arginine methylationDANA-FARBER CANCER INST2023–2028
- Molecular mechanisms and therapeutic targeting of activated NRF2 signaling in MiT/TFE translocation renal cell carcinomaDANA-FARBER CANCER INST2023–2028
- Molecular mechanisms and therapeutic targeting of activated NRF2 signaling in MiT/TFE translocation renal cell carcinomaDANA-FARBER CANCER INST2023–2028
- Targeting the CDK4/6 pathway in MiT/TFE-translocation renal cell carcinomaDANA-FARBER CANCER INST2025–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
